Aragon Pharmaceuticals Receives $22,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f63a0b96-de96-4815-837a-947ab4dea4a7&Preview=1 - Date
4/23/2010 - Company Name
Aragon Pharmaceuticals - Mailing Address
4215 Sorrento Valley Blvd. San Diego, CA 92121 - Company Description
Aragon Pharmaceuticals is a San Diego based biopharmaceutical company focused on developing a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. - Website
http://www.aragonpharmaceuticals.com - Transaction Type
Venture Equity - Transaction Amount
$22,000,000 - Transaction Round
Series B - Proceeds Purposes
This financing will allow us to advance ARN-509 into clinical trials and continue the discovery and development of selective androgen receptor degraders and selective estrogen receptor degraders for the treatment of prostate and breast cancers. - M&A Terms
- Venture Investor
Aisling Capital - Venture Investor
OrbiMed - Venture Investor
The Column Group
